DNA vs FTRE

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 03, 2026

DNA

35.0
AI Score
VS
FTRE Wins

FTRE

49.3
AI Score

Investment Advisor Scores

DNA

35score
Recommendation
SELL

FTRE

49score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric DNA FTRE Winner
Revenue 39.63M 1.31B FTRE
Net Income -129.30M -36.80M FTRE
Net Margin -326.3% -2.8% FTRE
Operating Income -129.92M 11.40M FTRE
ROE -30.8% -7.0% FTRE
ROA -13.1% -1.4% FTRE
Total Assets 990.05M 2.71B FTRE
Cash 84.53M 168.60M FTRE
Current Ratio 4.57 0.96 DNA

Relative Price Performance (Last 90 Days)

DNA 1M: +75.7% · 3M: +22.2% FTRE 1M: +8.9% · 3M: +12.0%

Current Technical Phase

DNA

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 75

RSI (14): 74.6 · Price: $12.35

FTRE

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (2.9% over 20 days), RSI 57

RSI (14): 56.8 · Price: $20.00

Fundamentals Snapshot

Metric DNA FTRE
Market Cap — —
Forward P/E -4.3 17.7
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth -0.5% 0.0%
Gross Margin 0.7% 0.2%
Operating Margin -2.8% 0.0%
EPS -5.19 -0.83
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, FTRE is currently the stronger investment candidate, winning 8 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.